The Joint Action on Personalized Cancer Medicine (JA PCM) launched with €25.3 million from the EU to expand equitable access to personalized prevention, early detection and treatment across 29 countries. The four-year program will support pilot projects on polygenic risk scores, molecular tumor boards, liquid biopsy quality assessment, and digital tools for remote monitoring. Separately, PharosAI secured UK government backing to build multimodal cancer datasets on 10x Genomics’ Xenium platform, combining decades of NHS archived samples with AI models for diagnosis and drug discovery. The effort will generate spatially resolved, linked genomic and imaging data accessible to researchers. Together these initiatives reflect coordinated European investments in infrastructure—clinical, genomic, and AI—that aim to standardize personalized oncology tools across regulatory environments and broaden access to precision approaches.